EDIT
Editas Medicine, Inc.
There isn't enough reported data to score EDIT yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
EDIT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
EDIT's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
EDIT PE Valuation
EDIT has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
EDIT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect EDIT's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
EDIT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.62 | +$1.76 |
| Q2 2026 | -$0.75 | +$2.10 |
| Q1 2026 | -$1.23 | +$1.81 |
| Q4 2025 | -$1.89 | +$0.99 |
| Q3 2025 | -$2.38 | +$0.15 |
| Q2 2025 | -$2.85 | -$0.52 |
| Q1 2025 | -$3.04 | -$0.97 |
| Q4 2024 | -$2.88 | -$0.86 |
EDIT has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
EDIT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $10.4M | +37% |
| Q2 2026 | $11.9M | +232% |
| Q1 2026 | $2.8M | -39% |
| Q4 2025 | $24.7M | -19% |
| Q3 2025 | $7.5M | +12266% |
| Q2 2025 | $3.6M | +597% |
| Q1 2025 | $4.7M | +310% |
| Q4 2024 | $30.6M | -49% |
EDIT's revenue is recovering but still below its 2020 peak: $10M last quarter, up 37% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -234% | +91 points |
| Q2 2026 | -156% | +1285 points |
| Q1 2026 | -883% | +752 points |
| Q4 2025 | -31% | +121 points |
| Q3 2025 | -325% | +107324 points |
| Q2 2025 | -1441% | +12576 points |
| Q1 2025 | -1635% | +4267 points |
| Q4 2024 | -152% | -112 points |
EDIT's operating margin was −234% last quarter, up 91 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over EDIT on profitability, with a higher operating margin.
EDIT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$21.2M | +$10.1M |
| Q2 2026 | -$29.7M | +$20.5M |
| Q1 2026 | -$23.2M | +$24.8M |
| Q4 2025 | -$36.4M | +$14.9M |
| Q3 2025 | -$31.3M | +$24.2M |
| Q2 2025 | -$50.2M | +$10.3M |
| Q1 2025 | -$47.9M | +$3.8M |
| Q4 2024 | -$51.3M | -$27.8M |
EDIT has burned cash in almost every quarter: −$110M over the past year, against −$181M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over EDIT on cash generation, producing positive trailing cash flow while its opponent burns cash.
EDIT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +29% | +34.3M shares |
| 1 year | +71% | +63.5M shares |
| 3 years | +88% | +72M shares |
| 5 years | +125% | +85.4M shares |
| Available history | +207% | +104M shares |
EDIT has 154M diluted shares, up 71% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over EDIT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
EDIT Net Leverage
EDIT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
EDIT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.6 | Neutral |
| Stochastic | 20.1 | Neutral |
EDIT's weekly RSI is 42 (neutral) and its Stochastic is 20 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
EDIT PE vs Healthcare Sector
EDIT has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
EDIT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.53 | 15% below |
| 20 week MA | $2.79 | 23% below |
| 50 week MA | $2.60 | 18% below |
| 100 week MA | $2.37 | 9.7% below |
| 200 week MA | $4.70 | 54% below |
EDIT is in a downtrend: it's below all five of its weekly moving averages, and 54% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
EDIT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $30.5 | $83.5 | +174% |
| 2021 | $83.5 | $29.9 | -64% |
| 2022 | $29.9 | $8.84 | -70% |
| 2023 | $8.84 | $10.1 | +15% |
| 2024 | $10.1 | $1.21 | -88% |
| 2025 | $1.21 | $2.17 | +79% |
| 2026 YTD | $2.17 | $2.14 | -1.4% |
EDIT has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.